Experimental drug combo shows promise for Tough-to-Treat leukemia
NCT ID NCT03330821
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding pevonedistat to standard chemotherapy (cytarabine and idarubicin) can improve remission rates in people newly diagnosed with high-risk acute myeloid leukemia (AML). About 53 participants will receive the combination to find the best dose and check for side effects. The goal is to see if this approach leads to more complete remissions than standard treatment alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pevonedistat (TAK-924) combined with cytarabine and idarubicin
- What this could lead to
- If successful, this combination could improve remission rates for people with high-risk acute myeloid leukemia, offering a more effective initial treatment option.
- What could go wrong
- This is an early-phase trial with only 53 participants, so results may not apply to all patients. The added drug may increase side effects without improving outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Los Angeles County-USC Medical Center
Los Angeles, California, 90033, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Arizona Cancer Center - North Campus
Tucson, Arizona, 85724, United States
-
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?